Relating biomarkers to efficacy and the efficacy curve: a review of EGFR therapies in oncology.
Personalized medicine attempts to provide the right drug to the right patient. In oncology, the mechanisms driving an individual's tumor need to be identified for appropriate therapy selection. Progressing from an individual's biomarker characterization to a population-based characterization is necessary for clinical trial design and success. This article will review recent EGF receptor therapy trials in non-small-cell lung cancer and colorectal cancer, and in defined subgroups will demonstrate a relationship between biomarkers and efficacy (response rate) that can be visualized with an 'efficacy curve'. A method for predicting therapeutic response in subgroups of patients defined by biomarker tests is provided.